Board summary
Key figures
49,912
Registered population
57.9% aged 18–64
23.5%
Aged 65+
ICB 19.0% · England 17.9%
4.2%
Ethnic minority (non-White)
1.9% Asian · England 9.6%
18.1%
In IMD quintile 1
ICB 31.9% · England 21.0%
~9,586
Core20 residents (est.)
Resident basis; registered basis ~8,812 · see page 3
8,792
Hypertension register
+3.09% in 3 yrs · England +5.60%
468
SMI register
11.7% of Wirral (LAD)'s
1,035
COPD register
Reviews -1.13% in 3 yrs
Forecast to 2030
9,563
Hypertension patients, 2030
+771 on today
66.2%
QRISK ≥20% on statins, 2030
+1.96pp over 3 yrs
6.2%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma and COPD annual reviews trail comparators.
Asthma reviews sit at 59.4% (England 65.7%), leaving about 1,500 of 3,597 patients unreviewed; COPD reviews sit at 70.0% (England 76.4%).
Under-80 blood pressure and lipid therapy lag.
Despite 90.8% recent blood pressure recording, under-80 control is 64.4% (England 67.8%) and QRISK ≥ 20% lipid therapy is 62.0% (Wirral 65.8%).
Severe mental illness physical checks outpace England.
Blood pressure checks reached 90.2% (+10.7 pp over 2023 to 2025; England 83.4%) and BMI recording reached 85.8% (+12.0 pp; England 82.1%).
Population, age and ethnicity
With 23.5% aged 65+, an older population may increase PCN chronic disease caseloads
Healthier South Wirral PCN serves 49,912 registered patients across five practices. The population is older than benchmarks: 23.5% (11,747 patients) are aged 65+, above Wirral (20.7%), the ICB (19.0%) and England (17.9%). Working-age adults (18–64) comprise 57.9% and children (0–17) 18.6%. Usual residents are 95.8% White (Wirral 95.2%, ICB 93.0%, England 81.1%), with an ethnic minority share of 4.2% (Asian 1.9%). ONS list growth is projected at 1.5% to 2030 (Wirral 1.2%, ICB 2.3%, England 2.3%). Ethnicity reflects Census usual residents rather than GP registrations, and projection methodology remains unverified.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Wirral (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Wirral LA) | 1,517 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 78.3% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.2% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Wirral LA) | 753 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Wirral LA) | 25.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 share is 18.1% overall but spans 37.4 pp across member practices
Across the PCN, 18.1% of registered patients live in Core20 areas (national IMD deciles 1 and 2), below Wirral (34.8%), the ICB (31.9%) and England (21.0%). The weighted practice share is 17.7%, an unresolved 0.43 percentage point discrepancy. Practice shares span 37.4 pp: Sunlight Group Practice has 37.4% (estimated 6,487 patients), Orchard Surgery has 14.4% (estimated 1,008 patients), Eastham Group Practice has 11.8% (estimated 1,317 patients), and Civic Medical Centre and Spital Surgery record 0.0%. Prioritise Core20 resources toward Sunlight Group Practice, where patient volume is heavily concentrated.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
468
SMI register
0.93% recorded prevalence
552
Learning disability register
1.10% recorded prevalence
33
Care homes, 902 beds
In the PCN catchment
10.9%
Provide unpaid care
Wirral (LAD), Census 2021
The PCN records 552 learning disability patients (1.1%, Wirral 0.8%, England 0.6%) and 468 severe mental illness patients (0.9%). Its catchment contains 33 care homes (902 beds). Wirral's 10.9% unpaid carer rate and 7 rough sleepers are borough figures that cannot be extrapolated. Learning disability prevalence is above Wirral and England benchmarks, so annual health checks for this cohort may represent the larger inclusion-health workload to protect.
Severe mental illness: physical health checks
Over 2023 to 2025, SMI blood pressure checks rose +10.7 pp (England +4.4 pp) to 90.2% and BMI checks rose +12.0 pp (England +5.1 pp) to 85.8%. Smoking cessation offers fell 2.6 pp (England +0.1 pp) to 95.4%.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
8,792
Hypertension register
+3.09%
Register growth, 3 yrs
Wirral (LAD) +6.35% · England +5.60%
+1.33pp
BP control, under 80
≤140/90 · −0.97pp aged 80+
+771
More patients by 2030
Forecast 9,563 (18.65%)
Hypertension case-finding and control
Hypertension prevalence is 17.6% (8,792 patients), below Wirral (18.0%) but above the ICB (16.8%) and England (15.2%). Recent blood pressure checks reach 90.8% (Wirral 89.2%, ICB 88.3%, England 90.0%), yet control under age 80 lags at 64.4% against 66.5% in Wirral, 66.4% in the ICB and 67.8% nationally. For patients aged 80 and over, control fell 1.2% over 2023 to 2025 (England +2.2%) to 80.9% (Wirral 80.1%, ICB 80.0%, England 81.2%). This disparity could reflect titration delays, which clinical audit would test, though crude prevalence does not establish unmet need. Lower blood pressure control despite strong testing rates suggests prioritising medication titration and structured follow-up for patients aged under 80.
Lipids and statins
Patients with QRISK ≥ 20% receiving lipid-lowering therapy stand at 62.0%, below Wirral (65.8%), the ICB (63.2%) and England (63.6%), after 2023 to 2025 growth of +3.3% lagged England (+6.2%). Trailing lipid coverage relative to benchmarks may suggest reviewing primary prevention recall for high-risk patients.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 110,824 | £1.70 | £1.71 | £1.86 | £188,401 |
| Cardiovascular (all), 2025 | 150,187 | £5.71 | £4.37 | £3.33 | £857,568 |
In 2026, the PCN prescribed 110,824 lipid-regulating items at £1.70 each, below Wirral (£2.00), the ICB (£1.71) and England (£1.86), spending £17,732 less than at England's unit cost across 110,824 items. Unit cost is an expenditure indicator and does not reflect clinical appropriateness.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−2.01%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+2.11%
Asthma prevalence, PCN 3-yr % change
Asthma annual reviews fell 2.0% over 2023 to 2025 (England +4.4%) to 59.4% (England 65.7%, Wirral 63.2%, ICB 62.3%), leaving about 1,500 of 3,597 registered patients unreviewed. Second-hand smoke recording for asthmatics aged 6-19 was 67.7% (294 patients), below England (78.8%) by 11.1 percentage points. COPD reviews fell 1.1% (England +2.8%) to 70.0% (England 76.4%), while COPD prevalence fell 6.7% (England +2.6%) to 2.1% (1,035 patients; gap range -89 to +265).
Cancer register and children's immunisation
Cancer register prevalence is 5.3% (2,676 patients; England 3.8%, Wirral 4.8%, ICB 4.3%), growing +7.6% over 2023 to 2025 (England +9.0%). In Q1 2025/26 childhood immunisations, age-five MMR dose 1 reached 96.0% (England 91.7%), but dose 2 was 89.7% (England 82.8%), a 6.3 pp drop falling below the 95% target by 5.3 pp.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
In 2022, 55.5% of cancers with known stage in NHS Cheshire and Merseyside ICB were diagnosed at stage 1 or 2 (7,482 of 13,490; England 55.3%), sitting 19.5 pp below the 75.0% national ambition by 2028. Reaching the ambition requires about 2,640 additional early diagnoses across the ICB, where known stage was recorded for 72.8% of cases (13,490 of 18,522; England 67.0%). These system-level figures describe regional pathways, not PCN performance. In Healthier South Wirral PCN, cervical screening coverage is 72.2% overall, but stands at 66.8% at Sunlight Group Practice.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), Wirral University Teaching Hospital NHS Foundation Trust achieved 77.6% on the 62-day cancer referral to treatment standard against the 85.0% standard (ICB 76.2%, England 71.2%). On the 28-day faster diagnosis standard, the trust reached 74.7% against the 75.0% standard (ICB 77.2%, England 79.3%). In July 2026 diagnostics, patients waiting 6+ weeks at the trust were 1.0% for non-obstetric ultrasound, 1.5% for MRI, and 1.5% for CT (England 9.9%). These figures reflect secondary care activity rather than PCN performance.
| Pathways within standard (%) | Wirral | Liverpool | Mersey and West Lancashire | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 74.71 | 75.47 | 72.39 | 77.25 | 79.32 |
| 31-day treatment (96%) | 92.53 | 90.51 | 95.46 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 77.65 | 73.26 | 77.96 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Wirral | Liverpool | Mersey and West Lancashire | England |
|---|---|---|---|---|
| MRI | 1.54 | 6.42 | 14.04 | 21.40 |
| CT | 1.55 | 0.71 | 13.08 | 9.92 |
| Echocardiography | 5.07 | 12.55 | 34.88 | 28.48 |
| Colonoscopy | 32.81 | 33.14 | 18.04 | 30.83 |
| Gastroscopy | 17.73 | 44.99 | 18.17 | 29.02 |
| All 15 DM01 tests | 5.02 | 11.50 | 21.17 | 23.14 |
| Community services activity | Wirral residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 58,870 | 541,280 |
| Referrals | 13,315 | 97,150 |
| Patients with a contact | 17,205 | 146,240 |
Community services (residents of Wirral), Jun 2026 (provisional). In June 2026, provisional community services dataset figures show that adults aged 65 and over accounted for 66.1% of all community contacts among Wirral local authority residents (38,930 of 58,870 contacts). This borough-level activity highlights substantial elderly community care use across the area, although activity is not reported at PCN level.
Practice variation and patient experience
GP phone access and QOF vaccination achievement vary sharply across the five practices
Across 2025/26 QOF domains, clinical achievement remains high at 95.9% to 100.0%, but vaccination and immunisation achievement spans 71.5 pp, ranging from 28.5% at Sunlight Group Practice to 100.0% at Spital Surgery (England 55.2%). QOF overall achievement ranges from 88.5% at Sunlight Group Practice to 98.4% at Spital Surgery (England 92.5%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Spital Surgery | 112 | 0.0 | 87.4% | 74.3% | 95.4% |
| Civic | 119 | 0.0 | 73.7% | 78.3% | 85.2% |
| Sunlight | 134 | 37.4 | 57.5% | 69.8% | 81.3% |
| Eastham | 104 | 11.8 | 60.5% | 54.9% | 79.9% |
| Orchard Surgery | 105 | 14.4 | 49.9% | 66.0% | 75.8% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fifteen of 25 tracked measures trail England trends despite severe mental illness gains
Over 2023 to 2025, 15 of 25 tracked measures trailed England's three-year trend. The widest relative lags were in respiratory reviews: asthma reviews fell 2.0% (England +4.4%) to 59.4%, and COPD reviews fell 1.1% (England +2.8%) to 70.0%. Smoking cessation support fell 2.6 pp (England +0.1 pp). Conversely, severe mental illness checks improved: BMI recording rose +12.0 pp (England +5.1 pp) to 85.8% and blood pressure checks rose +10.7 pp (England +4.4 pp) to 90.2%. Adapting severe mental illness recall systems could help improve lagging chronic disease reviews.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
COPD register
Asthma reviews
COPD reviews
BP control, 80+
QRISK statin treatment
BMI record (SMI)
BP check (SMI)
Alcohol record (psychosis)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Wirral (LAD) | Asset | PCN | Wirral (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 33 (902 beds) | n/a | Schools (catchment) | 51 | n/a |
| Children's centres | 4 | 16 | Places of worship | 37 | 171 |
| Libraries | 4 | 18 | Primary schools (LA maintained) | 12 | 52 |
| Primary academies | 9 | 36 | Special schools | n/a | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma annual review recall
Asthma annual reviews sit at 59.4% (Wirral 63.2%, ICB 62.3%, England 65.7%) after a -2.0% 3-year change (England +4.4%), leaving 1,461 (about 1,500) of 3,597 patients unreviewed. For discussion: practices could run single-template asthma recalls prioritising high-Core20 lists, offering flexible review slots alongside inhaler checks. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
COPD register validation and review recall
COPD prevalence is 2.1% (1,035 patients; Wirral 2.6%, England 1.9%, gap range -89 to +265) after a -6.7% 3-year change (England +2.6%); annual reviews are 70.0% (England 76.4%). For discussion: practices could audit records for patients with repeated respiratory prescribing lacking a COPD code, alongside structured annual review recall. Moderate effort to run.
Evidence base: the copd register is the cohort for spirometry-confirmed diagnosis, annual review and inhaler technique; register size and growth set the workload those interventions must cover.
Policy anchor: Core20PLUS5 adults: chronic respiratory disease (COPD vaccination and exacerbation reduction); Tobacco and Vapes Bill: smokefree generation.
Option 3
Hypertension titration and lipid therapy review
Hypertension prevalence is 17.6% (8,792 patients; Wirral 18.0%, England 15.2%; gap range -1,191 to +207). Under-80 BP control is 64.4% (England 67.8%) and QRISK ≥ 20% lipid therapy is 62.0% (Wirral 65.8%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult frailty review alignment (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 practice outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Smoking cessation offer audit (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension titration and recall review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall outreach (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening uptake campaign (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | Practice |
| Primary care telephony access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · COPD register validation and review recall (p12) | COPD register · COPD: QOF prevalence · COPD patients with a review in the last 12 months | Core20PLUS5 approach · Tobacco and Vapes Bill | PCN |
| Option 3 · Hypertension titration and lipid therapy review (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients with a recent BP reading | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
